CRISPR Therapeutics Announces Phase 1 Clinical Trial Results for zugo-cel in Autoimmune Diseases
CRSP CRISPR Therapeutics AG
$40.37 -4.43%
View chart & analysis → - 1CRISPR Therapeutics reported updated results from its ongoing Phase 1 clinical trial of zugo-cel.
- 2An 83% clinical response rate was recorded among patients in the systemic sclerosis cohort receiving standard lymphodepletion therapy at month 3, with 5 out of 6 patients responding.
- 3No dose-limiting toxicities have been observed in 21 patients to date.
So what's the key point?
CRISPR Therapeutics announced clinical trial results for an autoimmune disease treatment. Five out of six patients showed a response, and no side effects were observed.
Source InvestorsHub +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.